Heterogeneity in transmissibility and shedding

SARS-CoV-2 via droplets and aerosols

Paul Z. Chen[1], Niklas Bobrovitz[2-4], Zahra Premji[5], Marion Koopmans[6], David N. Fisman[7,8], Frank X. Gu[1,9]*

Affiliations:

[1]Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto, Canada

[2]Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

[3]Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

[4]O'Brien Institute of Public Health, University of Calgary, Calgary, Canada

[5]Libraries & Cultural Resources, University of Calgary, Calgary, Canada

[6]Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands

[7]Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

[8]Division of Infectious Diseases, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

[9]Institute of Biomedical Engineering, University of Toronto, Toronto, Canada

*Correspondence to: f.gu@utoronto.ca

Abstract

Understanding the factors that mediate overdispersion in SARS-CoV-2 transmissibility is crucial

towards mitigating the COVID-19 pandemic. Using a systematically developed dataset, we

meta-analyze respiratory viral loads (rVLs) of SARS-CoV-2, SARS-CoV-1 and influenza

A(H1N1)pdm09 from 15 countries and model infectiousness by shedding viable virus via

droplets and aerosols. Our results indicate heterogeneity in rVL as an intrinsic virological factor

facilitating greater overdispersion in the COVID-19 pandemic than in the 2009 H1N1 pandemic.

For COVID-19, case heterogeneity remains broad throughout the infectious period, including for

pediatric and asymptomatic infections. Many cases inherently present minimal transmission risk,

whereas highly infectious individuals shed tens to thousands of SARS-CoV-2 virions/min via

droplets and aerosols while breathing, talking and singing. Coughing increases the

contagiousness, especially in close contact, of symptomatic cases relative to asymptomatic ones.

Our findings show how individual case variations influence SARS-CoV-2 transmissibility and

present considerations for disease control.

One Sentence Summary: Intrinsic case variation in respiratory viral load facilitates broad

overdispersion in SARS-CoV-2 transmissibility.

Main Text

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing

the coronavirus disease 2019 (COVID-19) pandemic with more than 50.9 million infections and

1.2 million deaths (as of 10 November 2020) (*1*). For respiratory virus transmission, airway

epithelial cells shed virions to the extracellular fluid before atomization (from breathing, talking,

singing, coughing and aerosol-generating procedures) partitions them into a polydisperse mixture

of particles that are expelled to the ambient environment. Aerosols (≤100 μm) can be inhaled

nasally, whereas droplets (>100 μm) tend to be excluded (*2, 3*). For direct transmission, droplets

must be sprayed ballistically onto susceptible tissue (*4*). Hence, droplets predominantly deposit

on nearby surfaces, potentiating indirect transmission. Aerosols can be further categorized based

on typical travel characteristics: short-range aerosols (50-100 μm) tend to settle within 2 m; long-

range ones (10-50 μm) often travel beyond 2 m based on emission force; and buoyant aerosols

(≤10 μm) remain suspended and travel based on airflow profiles for minutes to many hours (*4,*

5). Although proximity has been associated with infection risk for COVID-19 (*6*), studies have

also suggested that long-range airborne transmission occurs conditionally (*7-9*).

While the basic reproductive number has been estimated to be 2.0-3.6 (*10, 11*),

transmissibility of SARS-CoV-2 is highly overdispersed (dispersion parameter k, 0.10-0.58),

with numerous instances of superspreading (*7-9*) and few cases (10-20%) causing many

secondary infections (80%) (*12-14*). Similarly, few cases drive the transmission of SARS-CoV-1

(k, 0.16-0.17) (*15*), whereas influenza A(H1N1)pdm09 transmits more homogeneously (k, 7.4-

14.4) (*16, 17*), despite both viruses spreading by contact, droplets and aerosols (*18, 19*).

Although understanding the determinants of overdispersion is crucial towards characterizing

transmissibility and developing effective strategies to limit infection (*20*), mechanistic

associations for *k* remain unclear. As an empirical estimate, *k* depends on myriad extrinsic

(behavioral, environmental and invention) and host factors. Nonetheless, *k* remains similar across

distinct outbreaks of a virus (*15*), suggesting that intrinsic virological factors mediate

overdispersion for emerging infections.

Here, we investigated how intrinsic case variation in rVL facilitates overdispersion in

SARS-CoV-2 transmissibility. By systematic review, we developed a comprehensive dataset of

rVLs from cases of COVID-19, SARS and A(H1N1)pdm09. Using comparative meta-analyses,

we found that heterogeneity in rVL was associated with overdispersion among these emerging

infections. To assess potential sources of case heterogeneity, we analyzed SARS-CoV-2 rVLs

across age and symptomatology subgroups as well as disease course. To interpret the influence

of heterogeneity in rVL on individual infectiousness, we modelled likelihoods of shedding viable

virus via respiratory droplets and aerosols.

Systematic review

We conducted a systematic review on virus quantitation in respiratory specimens taken during

the infectious periods of SARS-CoV-2 (-3 to 10 days from symptom onset [DFSO]) (*21-23*),

SARS-CoV-1 (0-20 DFSO) (*24*) and A(H1N1)pdm09 (-2 to 9 DFSO) (*25*) (Methods). The

systematic search (Tables S1 to S5) identified 4,274 results. After screening and full-text review,

63 studies met the inclusion criteria and contributed to the systematic dataset (Fig. 1) ($N = 9,616$

total specimens), which included adult ($N = 5,030$) and pediatric ($N = 1,594$) cases from 15

countries and specimen measurements for asymptomatic ($N = 2,387$), presymptomatic ($N = 28$)

and symptomatic ($N = 7,146$) infections. According to a hybrid Joanna Briggs Institute critical

appraisal checklist, risk of bias was low for most contributing studies (Table S6).

Association of overdispersion with heterogeneity in rVL

We hypothesized that individual case variation in rVL facilitates the distinctions in k among

COVID-19, SARS and A(H1N1)pdm09. For each study in the systematic dataset, we used

specimen measurements (viral RNA concentration in a respiratory specimen) to estimate rVLs

(viral RNA concentration in the respiratory tract) (Methods). To investigate the relationship

between k and heterogeneity in rVL, we performed a meta-regression using each contributing

study (fig. S1), which showed a weak, negative association between the two variables (meta-

regression slope t-test: $P = 0.040$, Pearson's $r = -0.26$).

Using contributing studies with low risk of bias, meta-regression (Fig. 2) showed a

strong, negative association between k and heterogeneity in rVL (meta-regression slope t-test: P

$< 10^{-8}$, Pearson's $r = -0.73$). In this case, each unit increase (1 $\log_{10}$ copies/ml) in the SD of rVL

decreased $\log(k)$ by a factor of -1.41 (95% confidence interval [CI]: -1.80 to -1.03), suggesting

that broader heterogeneity in rVL facilitates greater overdispersion in the transmissibility of

SARS-CoV-2 than of A(H1N1)pmd09. To investigate mechanistic aspects of this association, we

conducted a series of analyses on rVL and then modelled the influence of heterogeneity in rVL

on individual infectiousness.

Meta-analysis and subgroup analyses of rVL

We first compared rVLs among the emerging infections. We performed a random-effects meta-

analysis (fig. S2), which assessed the expected rVL when encountering a COVID-19, SARS or

A(H1N1)pdm09 case during the infectious period. This showed that the expected rVL of SARS-

CoV-2 was not different from that of SARS-CoV-1 (one-sided Welch's t-test: $P = 0.102$) but

lesser than that of A(H1N1)pdm09 ($P = 0.044$). We also performed random-effects subgroup

analyses for COVID-19 (Fig. 3), which showed that expected SARS-CoV-2 rVLs were similar

between pediatric and adult cases ($P = 0.409$) and comparable between

symptomatic/presymptomatic and asymptomatic infections ($P = 0.107$). Since these meta-

analyses had significant between-study heterogeneity among the mean estimates (Cochran's Q

test: $P < 0.001$ for each meta-analysis), we conducted risk-of-bias sensitivity analyses; meta-

analyses of low-risk-of-bias studies continued to show significant heterogeneity (figs. S3 to S7).

Distributions of rVL

We next analyzed rVL distributions. For all three viruses, rVLs best conformed to Weibull

distributions (fig. S8), and we fitted the entirety of individual sample data for each virus in the

systematic dataset (Fig. 4A and fig. S8N). While COVID-19 and SARS cases tended to shed

lesser virus than those with A(H1N1)pdm09 (fig. S2), broad heterogeneity in SARS-CoV-2 and

SARS-CoV-1 rVLs inverted this relationship for highly infectious individuals (Fig. 4A and fig.

S9, A to C). At the 90th case percentile (cp) throughout the infectious period, the estimated rVL

was 8.91 (95% CI: 8.83-9.00) $\log_{10}$ copies/ml for SARS-CoV-2, whereas it was 8.62 (8.47-8.76)

$\log_{10}$ copies/ml for A(H1N1)pdm09 (Table S7). The standard deviation (SD) of the overall rVL

distribution for SARS-CoV-2 was 2.04 $\log_{10}$ copies/ml, while it was 1.45 $\log_{10}$ copies/ml for

A(H1N1)pdm09, showing that heterogeneity in rVL was indeed broader for SARS-CoV-2.

To assess potential sources of heterogeneity in SARS-CoV-2 rVL, we compared rVL

distributions among COVID-19 subgroups. In addition to comparable mean estimates (Fig. 3),

adult, pediatric, symptomatic/presymptomatic and asymptomatic COVID-19 cases showed

similar rVL distributions (Fig. 4, B and C), with SDs of 2.04, 2.06, 2.01 and 2.02 $\log_{10}$

copies/ml, respectively. Thus, age and symptomatology minimally influenced case variation in

SARS-CoV-2 rVL during the infectious period.

SARS-CoV-2 kinetics during respiratory infection

To analyze the influences of disease course, we delineated individual SARS-CoV-2 rVLs by

DFSO and fitted the mean estimates to a mechanistic model for viral kinetics (Fig. 4D,

Methods). The outputs indicated that, on average, each productively infected cell in the airway

epithelium shed SARS-CoV-2 at 1.83 (95% CI: 0.69-2.97) copies/ml day^{-1} and infected up to

9.48 susceptible cells (Table S8). The turnover rate for infected epithelial cells was 0.55 (0.30-

0.79) days^{-1}, while the half-life of SARS-CoV-2 in the respiratory tract was 2.65 (1.39-28.2)

hours. By extrapolating the model to an initial rVL of 0 log$_{10}$ copies/ml, the estimated incubation

period was 5.09 days, which agrees with epidemiological findings (*10*). Conversely, the expected

duration of shedding was 30.4 DFSO. Thus, SARS-CoV-2 rVL increased exponentially after

infection, peaked around 1 DFSO along with the proportion of infected epithelial cells (fig. S10)

and then diminished exponentially.

To evaluate case heterogeneity across the infectious period, we fitted distributions for

each DFSO (Fig. 4E), which showed that high SARS-CoV-2 rVLs also increased from the

presymptomatic period, peaked at 1 DFSO and then decreased towards the end of the first week

of illness. For the 90th cp at 1 DFSO, the rVL was 9.83 (95% CI: 9.12-10.61) log$_{10}$ copies/ml, an

order of magnitude greater than the overall 90th-cp estimate. High rVLs between 1-5 DFSO were

elevated above the expected values from the overall rVL distribution (Table S7). At -1 DFSO,

the 90th-cp rVL was 8.30 (6.88-10.02) log$_{10}$ copies/ml, while it was 7.96 (7.37-8.58) log$_{10}$

copies/ml at 10 DFSO. Moreover, heterogeneity in rVL remained broad across the infectious

period, with SDs of 1.85-2.46 $\log_{10}$ copies/ml between -1 to 10 DFSO (fig. S9, H to S).

Likelihood that droplets and aerosols contain virions

Towards analyzing the influence of heterogeneity in rVL on individual infectiousness, we first

modelled the likelihood of respiratory particles containing viable SARS-CoV-2. Since rVL is an

intensive quantity, the volume fraction of virions is low and viral partitioning coincides with

atomization, we used Poisson statistics to model likelihood profiles. To calculate an unbiased

estimator of partitioning (the expected number of viable copies per particle), our method

multiplied rVL estimates with particle volumes during atomization and an assumed viability

proportion of 0.1% in equilibrated particles (Methods).

When expelled by the mean COVID-19 case during the infectious period, respiratory

particles showed low likelihoods of carrying viable SARS-CoV-2 (fig. S11B). Aerosols

(equilibrium aerodynamic diameter [d_a] ≤ 100 μm) were ≤0.69% (95% CI: 0.43-0.95%) likely to

contain a virion. Droplets also had low likelihoods: at d_a = 330 μm, they were 19.4% (18.5-

20.3%), 2.42% (2.15-2.69%) and 0.20% (0.16-0.24%) likely to contain one, two or three virions,

respectively.

COVID-19 cases with high rVLs, however, expelled particles with considerably greater

likelihoods of carrying viable copies (Fig. 5, A and B, and fig. S11, D and E). For the 80th cp

during the infectious period, aerosols (d_a ≤ 100 μm) were ≤36.6% (95% CI: 35.3-38.0%) likely

to carry at least one SARS-CoV-2 virion. For the 90th cp, this likelihood was ≤96.7% (96.5-

96.9%), with larger aerosols tending to contain multiple virions (fig. S11E). At 1 DFSO, these

estimates were greatest, and ≤65.2% (56.1-74.3%) of buoyant aerosols (d_a ≤ 10 μm) contained at

least one viable copy of SARS-CoV-2 for the 98th cp. When expelled by high cps, droplets ($d_a >$

100 µm) tended to contain tens to thousands of SARS-CoV-2 virions (fig. S11E and Fig. 5B)

Shedding SARS-CoV-2 via respiratory droplets and aerosols

Using the partitioning estimates in conjunction with published profiles of the particles expelled

by respiratory activities (fig. S12), we next modelled the rates at which talking, singing,

breathing and coughing shed viable SARS-CoV-2 across d_a (Fig. 5, C to F). Singing shed virions

more rapidly than talking based on the increased emission of aerosols. Voice amplitude,

however, had a significant effect on aerosol production, and talking loudly emitted aerosols at

similar rates to singing (fig. S12E). Based on the generation of larger aerosols and droplets,

talking and singing shed virions more rapidly than breathing (Fig. 5, C to E). Each cough shed

similar quantities of virions as in a minute of talking (Fig. 5, C and F).

Each of these respiratory activities expelled aerosols at greater rates than droplets, but

particle size correlated with the likelihood of containing virions. Talking, singing and coughing

expelled virions at greater proportions via droplets (80.6-86.0%) than aerosols (14.0-19.4%)

(Fig. 5G). Moreover, short-range aerosols predominantly mediated the virions (90.8-92.6%) shed

via aerosols while talking normally and coughing. In comparison, while singing, talking loudly

and breathing, buoyant (29.7-68.4%) and long-range (10.3-31.6%) aerosols carried a larger

proportion of the virions shed via aerosols (Fig. 5G).

Influence of heterogeneity in rVL on individual infectiousness

To interpret how heterogeneity in rVL influences individual infectiousness, we modelled total

SARS-CoV-2 shedding rates (over all particle sizes) for each respiratory activity (Fig. 5H and

fig. S13). Between the 1st and the 99th cps, the estimates for a respiratory activity spanned ≥8.55

orders of magnitude on each DFSO; cumulatively from -1 to 10 DFSO, they spanned 11.0 orders

of magnitude. Hence, many COVID-19 cases inherently presented minimal transmission risk,

whereas highly infectious individuals shed considerable quantities of SARS-CoV-2. For the 98th

cp at 1 DFSO, singing expelled 350 (95% CI: 36.2-4,213) virions/min to the ambient

environment, talking emitted 328 (33.9-3,945) virions/min, breathing exhaled 1.73 (0.18-20.7)

virions/min and coughing discharged 279 (28.8-3,350) virions/cough; these estimates were

approximately two orders of magnitude greater than those for the 86th cp. For the 98th cp at -1

DFSO, singing shed 14.5 (0.15-4,515) virions/min and breathing exhaled 7.13×10^{-2} (7.20×10^{-4}-

22.2) virions/min. The estimates at 9-10 DFSO were similar to these presymptomatic ones (Fig.

5H and fig. S13B). As indicated by comparable mean rVLs (Fig. 3) and heterogeneities in rVL

(Fig. 4, B and C), adult, pediatric, symptomatic/presymptomatic and asymptomatic COVID-19

subgroups presented similar distributions for shedding virions through these activities.

We also compared the influence of case variation on individual infectiousness between

A(H1N1)pdm09 and COVID-19. Aerosol spread accounted for approximately half of

A(H1N1)pdm09 transmission events (*19*), and the 50% human infectious dose for aerosolized

influenza A virus is approximately 1-3 virions in the absence of neutralizing antibodies (*26*).

Based on the model, 62.9% of A(H1N1)pdm09 cases were infectious (shed ≥1 virion) via

aerosols within 24 h of talking loudly or singing (fig. S14A). The estimate was 58.6% within 24

h of talking normally and 22.3% within 24 h of breathing. In comparison, 48.0% of COVID-19

cases shed ≥1 virion via aerosols in 24 h of talking loudly or singing (fig. S14C). Notably, only

61.4% of COVID-19 cases shed ≥1 virion via either droplets or aerosols in 24 h of talking loudly

or singing (fig. S14D). While the human infectious dose of SARS-CoV-2 by any exposure route

remains unelucidated, it must be at least one viable copy. Thus, at least 38.6% of COVID-19

cases were expected to present negligible risk to spread SARS-CoV-2 through either droplets or

aerosols in 24 h. The proportion of inherently infectious cases further decreased as the infectious

dose increased: 55.8, 42.5 and 25.0% of COVID-19 cases were expected to shed ≥ 2, ≥ 10 and

≥ 100 virions, respectively, in 24 h of talking loudly or singing.

While these analyses indicated that a greater proportion of A(H1N1)pdm09 cases were

inherently infectious, 18.8% of COVID-19 cases shed virions more rapidly than those infected

with A(H1N1)pdm09 (Fig. 4A). At the 98th cp for A(H1N1)pdm09, singing expelled 4.38 (2.85-

6.78) virions/min and breathing exhaled 2.15×10^{-2} (1.40×10^{-2}-3.34×10^{-2}) virions/min. Highly

infectious COVID-19 cases expelled virions at rates that were up to 1-2 orders of magnitude

greater than their A(H1N1)pdm09 counterparts (Fig. 5H and fig. S15).

Discussion

This study provided systematic analyses of several factors characterizing SARS-CoV-2

transmissibility. First, we found that broader heterogeneity in rVL facilitates greater

overdispersion for SARS-CoV-2 than A(H1N1)pdm09. Our results suggest that many COVID-

19 cases infect no one (*12-14*) because they inherently present minimal transmission risk via

droplets or aerosols, although behavioral and environmental factors can further abate risk.

Meanwhile, highly infectious cases can shed tens to thousands of SARS-CoV-2 virions/min. The

model estimates, when corrected to copies rather than virions, align with recent clinical findings

for exhalation rates of SARS-CoV-2 (*27*). In comparison, a greater proportion of

A(H1N1)pdm09 cases are infectious but shed virions at low rates, which concurs with more

uniform transmission and few superspreading events observed during the 2009 H1N1 pandemic

(*16, 17*). Moreover, our analyses suggest that heterogeneity in rVL may be generally associated

with overdispersion for viral respiratory infections. In this case, rVL distribution can serve as an

early correlate for transmission patterns, including superspreading, during outbreaks of novel

respiratory viruses, providing insight for disease control before large-scale epidemiological

studies empirically characterize *k*. When transmission is highly overdispersed, targeted

interventions may disproportionately mitigate infection (*20*), with models estimating that

focusing half of control efforts on the most infectious 20% of cases outperforms random control

policies threefold (*15*).

Second, we analyzed SARS-CoV-2 kinetics during respiratory infection. While

heterogeneity remains broad throughout the infectious period, rVL tends to peak at 1 DFSO and

be elevated for 1-5 DFSO, coinciding with the period of highest attack rates observed among

close contacts (*28*). These results indicate that transmission risk tends to be greatest soon after

illness rather than in the presymptomatic period, which concurs with large tracing studies (6.4-

12.6% of secondary infections from presymptomatic transmission) (*29, 30*) rather than early

temporal models (~44%) (*23*). Furthermore, our kinetic analysis suggests that, on average,

SARS-CoV-2 reaches diagnostic concentrations 1.58-3.03 days after respiratory infection (-3.51

to -2.06 DFSO), assuming assay detection limits of 1-3 $\log_{10}$ copies/ml, respectively, for

nasopharyngeal swabs immersed in 1 ml of transport media.

Third, we assessed the relative infectiousness of COVID-19 subgroups. As a common

symptom of COVID-19 (*31*), coughing sheds considerable numbers of virions via droplets and

short-range aerosols. Thus, symptomatic infections tend to be more contagious than

asymptomatic ones, providing one reason as to why asymptomatic cases transmit SARS-CoV-2

at lower relative rates (*32*), especially in close contact (*33*), despite similar rVLs and increased

contact patterns. Accordingly, children (48-54% of symptomatic cases present with cough) (*34,*

35) tend to be less contagious than adults (68-80%) (*31, 35*) based on tendencies of

symptomatology rather than rVL. Conversely, coughing sheds few virions via smaller aerosols.

Our analyses suggest that asymptomatic and symptomatic infections present comparable risks for

airborne spread, as do adult and pediatric cases. While singing and talking loudly, highly

infectious individuals shed tens to hundreds of SARS-CoV-2 virions/min via long-range and

buoyant aerosols.

Our study has limitations. The systematic search found a limited number of studies

reporting quantitative specimen measurements from the presymptomatic period, meaning these

estimates may be sensitive to sampling bias. Although additional studies have reported

semiquantitative metrics (cycle thresholds), these data were excluded because they cannot be

compared on an absolute scale due to batch effects (*36*), limiting use in compound analyses.

Furthermore, this study considered population-level estimates of the infectious periods, viability

proportions and rate profiles for respiratory particles, which omit individual or environmental

variation. Distinctions in phonetic tendencies and, especially for young children, respiratory

capacity lead to variation in particle emission rates (*37*). Some patients shed SARS-CoV-2 with

diminishing viability soon after symptom onset (*21*), whereas others produce replication-

competent virus for weeks (*38*). It remains unclear how case characteristics and environmental

factors affect the viability dynamics of SARS-CoV-2.

Taken together, our findings provide a potential path forward for disease control. They

support aerosol spread as a transmission mode for SARS-CoV-2, including for conditional

superspreading by highly infectious cases. However, with short durations of stay in well-

ventilated areas, the exposure risk for aerosols, including long-range and buoyant ones, remains

correlated with proximity to infectious cases (*2, 4*). Strategies to abate infection should limit

crowd numbers and duration of stay while reinforcing distancing, low voice amplitudes and

widespread mask usage; well-ventilated settings can be recognized as lower risk venues.

Coughing can shed considerable quantities of virions, while rVL tends to peak at 1 DFSO and

can be high throughout the infectious period. Thus, immediate, sustained self-isolation upon

illness is crucial to curb transmission from symptomatic cases. Collectively, our analyses

highlight the role of infections with high rVLs in propelling the COVID-19 pandemic. While

diagnosing COVID-19, qRT-PCR can also triage contact tracing, prioritizing these patients: for

nasopharyngeal swabs immersed in 1 ml of transport media, $\geq$7.14 (95% CI: 7.07-7.22) $\log_{10}$

copies/ml corresponds to the top 20% of COVID-19 cases. Doing so may identify asymptomatic

and presymptomatic infections more efficiently, a key step towards mitigation as the pandemic

continues.

References and Notes:

1. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect. Dis.* **20**, 533-534 (2020).
2. K. A. Prather, L. C. Marr, R. T. Schooley, M. A. McDiarmid, M. E. Wilson, D. K. Milton, Airborne transmission of SARS-CoV-2. *Science* **370**, 303-304 (2020).
3. C. J. Roy, D. K. Milton, Airborne transmission of communicable infection — the elusive pathway. *N. Engl. J. Med.* **350**, 1710-1712 (2004).
4. L. Liu, Y. Li, P. V. Nielsen, J. Wei, R. L. Jensen, Short-range airborne transmission of expiratory droplets between two people. *Indoor Air* **27**, 452-462 (2017).
5. J. J. Wei, Y. G. Li, Enhanced spread of expiratory droplets by turbulence in a cough jet. *Build. Environ.* **93**, 86-96 (2015).
6. D. K. Chu, E. A. Akl, S. Duda, K. Solo, S. Yaacoub, H. J. Schunemann, C.-S. U. R. G. E. s. authors, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* **395**, 1973-1987 (2020).
7. S. Y. Park, Y. M. Kim, S. Yi, S. Lee, B. J. Na, C. B. Kim, J. I. Kim, H. S. Kim, Y. B. Kim, Y. Park, I. S. Huh, H. K. Kim, H. J. Yoon, H. Jang, K. Kim, Y. Chang, I. Kim, H. Lee, J. Gwack, S. S. Kim, M. Kim, S. Kweon, Y. J. Choe, O. Park, Y. J. Park, E. K. Jeong, Coronavirus disease outbreak in call center, South Korea. *Emerg. Infect. Dis.* **26**, 1666-1670 (2020).
8. J. Y. Lu, J. N. Gu, K. B. Li, C. H. Xu, W. Z. Su, Z. S. Lai, D. Q. Zhou, C. Yu, B. Xu, Z. C. Yang, COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. *Emerg. Infect. Dis.* **26**, 1628-1631 (2020).
9. L. Hamner, P. Dubbel, I. Capron, A. Ross, A. Jordan, J. Lee, J. Lynn, A. Ball, S. Narwal, S. Russell, D. Patrick, H. Leibrand, High SARS-CoV-2 attack rate following exposure at a choir practice - Skagit County, Washington, March 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 606-610 (2020).
10. Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, R. Ren, K. S. M. Leung, E. H. Y. Lau, J. Y. Wong, X. Xing, N. Xiang, Y. Wu, C. Li, Q. Chen, D. Li, T. Liu, J. Zhao, M. Liu, W. Tu, C. Chen, L. Jin, R. Yang, Q. Wang, S. Zhou, R. Wang, H. Liu, Y. Luo, Y. Liu, G. Shao, H. Li, Z. Tao, Y. Yang, Z. Deng, B. Liu, Z. Ma, Y. Zhang, G. Shi, T. T. Y. Lam, J. T. Wu, G. F. Gao, B. J. Cowling, B. Yang, G. M. Leung, Z. Feng, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N. Engl. J. Med.* **382**, 1199-1207 (2020).
11. X. Hao, S. Cheng, D. Wu, T. Wu, X. Lin, C. Wang, Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature* **584**, 420-424 (2020).
12. R. Laxminarayan, B. Wahl, S. R. Dudala, K. Gopal, C. Mohan, S. Neelima, K. S. Jawahar Reddy, J. Radhakrishnan, J. A. Lewnard, Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science*, eabd7672 (2020).
13. A. Endo, S. Abbott, A. J. Kucharski, S. Funk, Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Research* **5**, (2020).
14. Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei, S. A. Truelove, T. Zhang, W. Gao, C. Cheng, X. Tang, X. Wu, Y. Wu, B. Sun, S. Huang, Y. Sun, J. Zhang, T. Ma, J. Lessler, T. Feng, Epidemiology and transmission of COVID-19 in 391 cases

345   and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *The*
346   *Lancet Infectious Diseases* **20**, 911-919 (2020).

347   15.   J. O. Lloyd-Smith, S. J. Schreiber, P. E. Kopp, W. M. Getz, Superspreading and the
348   effect of individual variation on disease emergence. *Nature* **438**, 355-359 (2005).

349   16.   M. G. Roberts, H. Nishiura, Early estimation of the reproduction number in the presence
350   of imported cases: pandemic influenza H1N1-2009 in New Zealand. *PLoS One* **6**, e17835
351   (2011).

352   17.   J. Brugger, C. L. Althaus, Transmission of and susceptibility to seasonal influenza in
353   Switzerland from 2003 to 2015. *Epidemics* **30**, 100373 (2020).

354   18.   I. T. Yu, Y. Li, T. W. Wong, W. Tam, A. T. Chan, J. H. Lee, D. Y. Leung, T. Ho,
355   Evidence of airborne transmission of the severe acute respiratory syndrome virus. *N.*
356   *Engl. J. Med.* **350**, 1731-1739 (2004).

357   19.   B. J. Cowling, D. K. M. Ip, V. J. Fang, P. Suntarattiwong, S. J. Olsen, J. Levy, T. M.
358   Uyeki, G. M. Leung, J. S. M. Peiris, T. Chotpitayasunondh, H. Nishiura, J. M.
359   Simmerman, Aerosol transmission is an important mode of influenza A virus spread.
360   *Nature Communications* **4**, 1935 (2013).

361   20.   E. C. Lee, N. I. Wada, M. K. Grabowski, E. S. Gurley, J. Lessler, The engines of SARS-
362   CoV-2 spread. *Science* **370**, 406-407 (2020).

363   21.   R. Wolfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Muller, D.
364   Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brunink, J.
365   Schneider, R. Ehmann, K. Zwirglmaier, C. Drosten, C. Wendtner, Virological assessment
366   of hospitalized patients with COVID-2019. *Nature* **581**, 465-469 (2020).

367   22.   M. M. Arons, K. M. Hatfield, S. C. Reddy, A. Kimball, A. James, J. R. Jacobs, J. Taylor,
368   K. Spicer, A. C. Bardossy, L. P. Oakley, S. Tanwar, J. W. Dyal, J. Harney, Z. Chisty, J.
369   M. Bell, M. Methner, P. Paul, C. M. Carlson, H. P. McLaughlin, N. Thornburg, S. Tong,
370   A. Tamin, Y. Tao, A. Uehara, J. Harcourt, S. Clark, C. Brostrom-Smith, L. C. Page, M.
371   Kay, J. Lewis, P. Montgomery, N. D. Stone, T. A. Clark, M. A. Honein, J. S. Duchin, J.
372   A. Jernigan, H.-S. Public, C. King, C. C.-I. Team, Presymptomatic SARS-CoV-2
373   infections and transmission in a skilled nursing facility. *N. Engl. J. Med.* **382**, 2081-2090
374   (2020).

375   23.   X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan,
376   X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao,
377   F. Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral shedding and
378   transmissibility of COVID-19. *Nat. Med.* **26**, 672-675 (2020).

379   24.   V. E. Pitzer, G. M. Leung, M. Lipsitch, Estimating variability in the transmission of
380   severe acute respiratory syndrome to household contacts in Hong Kong, China. *Am. J.*
381   *Epidemiol.* **166**, 355-363 (2007).

382   25.   D. K. Ip, L. L. Lau, N. H. Leung, V. J. Fang, K. H. Chan, D. K. Chu, G. M. Leung, J. S.
383   Peiris, T. M. Uyeki, B. J. Cowling, Viral shedding and transmission potential of
384   asymptomatic and paucisymptomatic influenza virus infections in the community. *Clin.*
385   *Infect. Dis.* **64**, 736-742 (2017).

386   26.   P. Fabian, J. J. McDevitt, W. H. DeHaan, R. O. Fung, B. J. Cowling, K. H. Chan, G. M.
387   Leung, D. K. Milton, Influenza virus in human exhaled breath: an observational study.
388   *PLoS One* **3**, e2691 (2008).

389   27.   J. Ma, X. Qi, H. Chen, X. Li, Z. Zhang, H. Wang, L. Sun, L. Zhang, J. Guo, L.
390   Morawska, S. A. Grinshpun, P. Biswas, R. C. Flagan, M. Yao, COVID-19 patients in

earlier stages exhaled millions of SARS-CoV-2 per hour. *Clin. Infect. Dis.*
10.1093/cid/ciaa1283 (2020).

28. H. Y. Cheng, S. W. Jian, D. P. Liu, T. C. Ng, W. T. Huang, H. H. Lin, C.-O. I. T.
Taiwan, Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and
risk at different exposure periods before and after symptom onset. *JAMA Intern Med* **180**,
1156-1163 (2020).

29. W. E. Wei, Z. Li, C. J. Chiew, S. E. Yong, M. P. Toh, V. J. Lee, Presymptomatic
transmission of SARS-CoV-2 — Singapore, January 23-March 16, 2020. *MMWR Morb.*
Mortal. Wkly. Rep. **69**, 411-415 (2020).

30. Z. Du, X. Xu, Y. Wu, L. Wang, B. J. Cowling, L. A. Meyers, Serial interval of COVID-
19 among publicly reported confirmed cases. *Emerg. Infect. Dis.* **26**, 1341-1343 (2020).

31. W. J. Guan, Z. Y. Ni, Y. Hu, W. H. Liang, C. Q. Ou, J. X. He, L. Liu, H. Shan, C. L. Lei,
D. S. C. Hui, B. Du, L. J. Li, G. Zeng, K. Y. Yuen, R. C. Chen, C. L. Tang, T. Wang, P.
Y. Chen, J. Xiang, S. Y. Li, J. L. Wang, Z. J. Liang, Y. X. Peng, L. Wei, Y. Liu, Y. H.
Hu, P. Peng, J. M. Wang, J. Y. Liu, Z. Chen, G. Li, Z. J. Zheng, S. Q. Qiu, J. Luo, C. J.
Ye, S. Y. Zhu, N. S. Zhong, C. China Medical Treatment Expert Group for, Clinical
characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* **382**, 1708-1720
(2020).

32. R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial
undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-
CoV-2). *Science* **368**, 489-493 (2020).

33. L. Luo, D. Liu, X. Liao, X. Wu, Q. Jing, J. Zheng, F. Liu, S. Yang, H. Bi, Z. Li, J. Liu,
W. Song, W. Zhu, Z. Wang, X. Zhang, Q. Huang, P. Chen, H. Liu, X. Cheng, M. Cai, P.
Yang, X. Yang, Z. Han, J. Tang, Y. Ma, C. Mao, Contact settings and risk for
transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: a
prospective cohort study. *Ann. Intern. Med.* 10.7326/M20-2671 (2020).

34. X. Lu, L. Zhang, H. Du, J. Zhang, Y. Y. Li, J. Qu, W. Zhang, Y. Wang, S. Bao, Y. Li, C.
Wu, H. Liu, D. Liu, J. Shao, X. Peng, Y. Yang, Z. Liu, Y. Xiang, F. Zhang, R. M. Silva,
K. E. Pinkerton, K. Shen, H. Xiao, S. Xu, G. W. K. Wong, T. Chinese Pediatric Novel
Coronavirus Study, SARS-CoV-2 infection in children. *N. Engl. J. Med.* **382**, 1663-1665
(2020).

35. C. C.-R. Team, Coronavirus disease 2019 in children - United States, February 12-April
2, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 422-426 (2020).

36. M. S. Han, J. H. Byun, Y. Cho, J. H. Rim, RT-PCR for SARS-CoV-2: quantitative versus
qualitative. *Lancet Infect. Dis.* 10.1016/S1473-3099(20)30424-2 (2020).

37. H.-L. Yen, S. Asadi, A. S. Wexler, C. D. Cappa, S. Barreda, N. M. Bouvier, W. D.
Ristenpart, Effect of voicing and articulation manner on aerosol particle emission during
human speech. *PLoS One* **15**, e0227699 (2020).

38. J. J. A. van Kampen, D. A. M. C. van de Vijver, P. L. A. Fraaij, B. L. Haagmans, M. M.
Lamers, N. Okba, J. P. C. van den Akker, H. Endeman, D. A. M. P. J. Gommers, J. J.
Cornelissen, R. A. S. Hoek, M. M. van der Eerden, D. A. Hesselink, H. J. Metselaar, A.
Verbon, J. E. M. de Steenwinkel, G. I. Aron, E. C. M. van Gorp, S. van Boheemen, J. C.
Voermans, C. A. B. Boucher, R. Molenkamp, M. P. G. Koopmans, C. Geurtsvankessel,
A. A. van der Eijk, Shedding of infectious virus in hospitalized patients with coronavirus
disease-2019 (COVID-19): duration and key determinants. medRxiv [preprint]
https://doi.org/10.1101/2020.06.08.20125310 (2020).

39.   D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, P. Group, Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* **6**, e1000097
(2009).
40.   J. P. T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, V. A. Welch,
Cochrane handbook for systematic reviews of interventions (John Wiley & Sons,
Chichester, UK, 2019).
41.   Z. Munn, T. H. Barker, S. Moola, C. Tufanaru, C. Stern, A. McArthur, M. Stephenson, E.
Aromataris, Methodological quality of case series studies: an introduction to the JBI
critical appraisal tool. *JBI Database System Rev Implement Rep* 10.11124/JBISRIR-D-
19-00099 (2019).
42.   S. Moola, Z. Munn, C. Tufanaru, E. Aromataris, K. Sears, R. Sfetcu, M. Currie, K. Lisy,
R. Qureshi, P. Mattis, P. Mu, "Chapter 7: systematic reviews of etiology and risk" in
Joanna Briggs Institute Reviewer's Manual. (The Joanna Briggs Institute, 2020), pp.
2019-05.
43.   Z. Munn, S. Moola, K. Lisy, D. Riitano, C. Tufanaru, Methodological guidance for
systematic reviews of observational epidemiological studies reporting prevalence and
cumulative incidence data. *Int J Evid Based Healthc* **13**, 147-153 (2015).
44.   K. M. Johnston, P. Lakzadeh, B. M. K. Donato, S. M. Szabo, Methods of sample size
calculation in descriptive retrospective burden of illness studies. *BMC Med. Res.
Methodol.* **19**, 9 (2019).
45.   N. Zhang, Y. Gong, F. Meng, Y. Shi, J. Wang, P. Mao, X. Chuai, Y. Bi, P. Yang, F.
Wang, Comparative study on virus shedding patterns in nasopharyngeal and fecal
specimens of COVID-19 patients. *Sci China Life Sci* 10.1007/s11427-020-1783-9 (2020).
46.   E. Lavezzo, E. Franchin, C. Ciavarella, G. Cuomo-Dannenburg, L. Barzon, C. Del
Vecchio, L. Rossi, R. Manganelli, A. Loregian, N. Navarin, D. Abate, M. Sciro, S.
Merigliano, E. De Canale, M. C. Vanuzzo, V. Besutti, F. Saluzzo, F. Onelia, M. Pacenti,
S. G. Parisi, G. Carretta, D. Donato, L. Flor, S. Cocchio, G. Masi, A. Sperduti, L.
Cattarino, R. Salvador, M. Nicoletti, F. Caldart, G. Castelli, E. Nieddu, B. Labella, L.
Fava, M. Drigo, K. A. M. Gaythorpe, C.-R. T. Imperial College, A. R. Brazzale, S.
Toppo, M. Trevisan, V. Baldo, C. A. Donnelly, N. M. Ferguson, I. Dorigatti, A. Crisanti,
Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* **584**,
425-429 (2020).
47.   L. Peng, J. Liu, W. Xu, Q. Luo, D. Chen, Z. Lei, Z. Huang, X. Li, K. Deng, B. Lin, Z.
Gao, SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs
specimens. *J. Med. Virol.*, (2020).
48.   K. K. To, O. T. Tsang, W. S. Leung, A. R. Tam, T. C. Wu, D. C. Lung, C. C. Yip, J. P.
Cai, J. M. Chan, T. S. Chik, D. P. Lau, C. Y. Choi, L. L. Chen, W. M. Chan, K. H. Chan,
J. D. Ip, A. C. Ng, R. W. Poon, C. T. Luo, V. C. Cheng, J. F. Chan, I. F. Hung, Z. Chen,
H. Chen, K. Y. Yuen, Temporal profiles of viral load in posterior oropharyngeal saliva
samples and serum antibody responses during infection by SARS-CoV-2: an
observational cohort study. *Lancet Infect. Dis.* **20**, 565-574 (2020).
49.   L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, J. Yu, M. Kang, Y. Song, J.
Xia, Q. Guo, T. Song, J. He, H. L. Yen, M. Peiris, J. Wu, SARS-CoV-2 viral load in
upper respiratory specimens of infected patients. *N. Engl. J. Med.* **382**, 1177-1179 (2020).
50.   J. M. Fajnzylber, J. Regan, K. Coxen, H. Corry, C. Wong, A. Rosenthal, D. Worrall, F.
Giguel, A. Piechocka-Trocha, C. Atyeo, S. Fischinger, A. Chan, K. T. Flaherty, K. Hall,

M. Dougan, E. T. Ryan, E. Gillespie, R. Chishti, Y. Li, N. Jilg, D. Hanidziar, R. M. Baron, L. Baden, A. M. Tsibris, K. A. Armstrong, D. R. Kuritzkes, G. Alter, B. D. Walker, X. Yu, J. Li, SARS-CoV-2 viral load is associated with increased disease severity and mortality. medRxiv [preprint] https://doi.org/10.1101/2020.07.15.20131789 (2020)

51. S. Zheng, J. Fan, F. Yu, B. Feng, B. Lou, Q. Zou, G. Xie, S. Lin, R. Wang, X. Yang, W. Chen, Q. Wang, D. Zhang, Y. Liu, R. Gong, Z. Ma, S. Lu, Y. Xiao, Y. Gu, J. Zhang, H. Yao, K. Xu, X. Lu, G. Wei, J. Zhou, Q. Fang, H. Cai, Y. Qiu, J. Sheng, Y. Chen, T. Liang, Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* **369**, m1443 (2020).

52. N. J. Lennon, R. P. Bhattacharyya, M. J. Mina, H. L. Rehm, D. T. Hung, S. Smole, A. Woolley, E. S. Lander, S. B. Gabriel, Comparison of viral levels in individuals with or without symptoms at time of COVID-19 testing among 32,480 residents and staff of nursing homes and assisted living facilities in Massachusetts. medRxiv [preprint] https://doi.org/10.1101/2020.07.20.20157792 (2020).

53. N. K. Shrestha, F. Marco Canosa, A. S. Nowacki, G. W. Procop, S. Vogel, T. G. Fraser, S. C. Erzurum, P. Terpeluk, S. M. Gordon, Distribution of transmission potential during nonsevere COVID-19 illness. *Clin. Infect. Dis.* 10.1093/cid/ciaa886 (2020).

54. F. Shi, T. Wu, X. Zhu, Y. Ge, X. Zeng, Y. Chi, X. Du, L. Zhu, F. Zhu, B. Zhu, L. Cui, B. Wu, Association of viral load with serum biomakers among COVID-19 cases. *Virology* **546**, 122-126 (2020).

55. I. F. Hung, K. C. Lung, E. Y. Tso, R. Liu, T. W. Chung, M. Y. Chu, Y. Y. Ng, J. Lo, J. Chan, A. R. Tam, H. P. Shum, V. Chan, A. K. Wu, K. M. Sin, W. S. Leung, W. L. Law, D. C. Lung, S. Sin, P. Yeung, C. C. Yip, R. R. Zhang, A. Y. Fung, E. Y. Yan, K. H. Leung, J. D. Ip, A. W. Chu, W. M. Chan, A. C. Ng, R. Lee, K. Fung, A. Yeung, T. C. Wu, J. W. Chan, W. W. Yan, W. M. Chan, J. F. Chan, A. K. Lie, O. T. Tsang, V. C. Cheng, T. L. Que, C. S. Lau, K. H. Chan, K. K. To, K. Y. Yuen, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* **395**, 1695-1704 (2020).

56. S. Iwasaki, S. Fujisawa, S. Nakakubo, K. Kamada, Y. Yamashita, T. Fukumoto, K. Sato, S. Oguri, K. Taki, H. Senjo, J. Sugita, K. Hayasaka, S. Konno, M. Nishida, T. Teshima, Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. *J. Infect.* **81**, e145-e147 (2020).

57. R. Perera, E. Tso, O. T. Y. Tsang, D. N. C. Tsang, K. Fung, Y. W. Y. Leung, A. W. H. Chin, D. K. W. Chu, S. M. S. Cheng, L. L. M. Poon, V. W. M. Chuang, M. Peiris, SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild coronavirus disease. *Emerg. Infect. Dis.* **26**, 2701-2704 (2020).

58. A. L. Wyllie, J. Fournier, A. Casanovas-Massana, M. Campbell, M. Tokuyama, P. Vijayakumar, J. L. Warren, B. Geng, M. C. Muenker, A. J. Moore, C. B. F. Vogels, M. E. Petrone, I. M. Ott, P. Lu, A. Venkataraman, A. Lu-Culligan, J. Klein, R. Earnest, M. Simonov, R. Datta, R. Handoko, N. Naushad, L. R. Sewanan, J. Valdez, E. B. White, S. Lapidus, C. C. Kalinich, X. Jiang, D. J. Kim, E. Kudo, M. Linehan, T. Mao, M. Moriyama, J. E. Oh, A. Park, J. Silva, E. Song, T. Takahashi, M. Taura, O. E. Weizman, P. Wong, Y. Yang, S. Bermejo, C. D. Odio, S. B. Omer, C. S. Dela Cruz, S. Farhadian,

R. A. Martinello, A. Iwasaki, N. D. Grubaugh, A. I. Ko, Saliva or nasopharyngeal swab
specimens for detection of SARS-CoV-2. *N. Engl. J. Med.* **383**, 1283-1286 (2020).
59. S. Baggio, A. G. L'Huillier, S. Yerly, M. Bellon, N. Wagner, M. Rohr, A. Huttner, G.
Blanchard-Rohner, N. Loevy, L. Kaiser, F. Jacquerioz, I. Eckerle, SARS-CoV-2 viral
load in the upper respiratory tract of children and adults with early acute COVID-19.
Clin. Infect. Dis. 10.1093/cid/ciaa1157 (2020).
60. C. Lucas, P. Wong, J. Klein, T. B. R. Castro, J. Silva, M. Sundaram, M. K. Ellingson, T.
Mao, J. E. Oh, B. Israelow, T. Takahashi, M. Tokuyama, P. Lu, A. Venkataraman, A.
Park, S. Mohanty, H. Wang, A. L. Wyllie, C. B. F. Vogels, R. Earnest, S. Lapidus, I. M.
Ott, A. J. Moore, M. C. Muenker, J. B. Fournier, M. Campbell, C. D. Odio, A.
Casanovas-Massana, I. T. Yale, R. Herbst, A. C. Shaw, R. Medzhitov, W. L. Schulz, N.
D. Grubaugh, C. Dela Cruz, S. Farhadian, A. I. Ko, S. B. Omer, A. Iwasaki, Longitudinal
analyses reveal immunological misfiring in severe COVID-19. *Nature* **584**, 463-469
(2020).
61. K. V. Argyropoulos, A. Serrano, J. Hu, M. Black, X. Feng, G. Shen, M. Call, M. J. Kim,
A. Lytle, B. Belovarac, T. Vougiouklakis, L. H. Lin, U. Moran, A. Heguy, A. Troxel, M.
Snuderl, I. Osman, P. Cotzia, G. Jour, Association of initial viral load in severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and
symptoms. *Am. J. Pathol.* **190**, 1881-1887 (2020).
62. O. Mitja, M. Corbacho-Monne, M. Ubals, C. Tebe, J. Penafiel, A. Tobias, E. Ballana, A.
Alemany, N. Riera-Marti, C. A. Perez, C. Suner, P. Laporte, P. Admella, J. Mitja, M.
Clua, L. Bertran, M. Sarquella, S. Gavilan, J. Ara, J. M. Argimon, J. Casabona, G.
Cuatrecasas, P. Canadas, A. Elizalde-Torrent, R. Fabregat, M. Farre, A. Forcada, G.
Flores-Mateo, E. Muntada, N. Nadal, S. Narejos, A. N. Gil-Ortega, N. Prat, J. Puig, C.
Quinones, J. Reyes-Urena, F. Ramirez-Viaplana, L. Ruiz, E. Riveira-Munoz, A. Sierra,
C. Velasco, R. M. Vivanco-Hidalgo, A. Sentis, G. B. C, B. Clotet, M. Vall-Mayans, B.
P.-C.-R. GROUP, Hydroxychloroquine for early treatment of adults with mild Covid-19:
a randomized-controlled trial. *Clin. Infect. Dis.* 10.1093/cid/ciaa1009 (2020).
63. P. Vetter, C. Eberhardt, B. Meyer, P. Martinez, G. Torriani, F. Pigny, S. Lemeille, S.
Cordey, F. Laubscher, D.-L. Vu, A. Calame, M. Schibler, F. Jacquerioz, G. Blanchard,
C.-A. Siegrist, L. Kaiser, A. Didierlaurent, i. eckerle, Daily viral kinetics and innate and
adaptive immune responses assessment in COVID-19: a case series. medRxiv [preprint]
https://doi.org/10.1101/2020.07.02.20143271 (2020).
64. Y. Xu, X. Li, B. Zhu, H. Liang, C. Fang, Y. Gong, Q. Guo, X. Sun, D. Zhao, J. Shen, H.
Zhang, H. Liu, H. Xia, J. Tang, K. Zhang, S. Gong, Characteristics of pediatric SARS-
CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat. Med.* **26**,
502-505 (2020).
65. J. H. Hurst, S. M. Heston, H. N. Chambers, H. M. Cunningham, M. J. Price, L. Suarez, C.
Crew, S. Bose, J. N. Aquino, S. T. Carr, S. M. Griffin, S. H. Smith, K. Jenkins, T. S.
Pfeiffer, J. Rodriguez, C. T. Demarco, N. A. De Naeyer, T. C. Gurley, R. Louzao, C. K.
Cunningham, W. J. Steinbach, T. N. Denny, D. J. Lugo, M. A. Moody, S. R. Permar, A.
T. Rotta, N. A. Turner, E. B. Walter, C. W. Woods, M. S. Kelly, SARS-CoV-2 infections
among children in the biospecimens from respiratory virus-exposed kids (BRAVE Kids)
Study. medRxiv [preprint] https://doi.org/10.1101/2020.08.18.20166835 (2020).

66. A. G. L'Huillier, G. Torriani, F. Pigny, L. Kaiser, I. Eckerle, Culture-competent SARS-
CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerg.*
Infect. Dis. **26**, 2494-2497 (2020).
67. M. S. Han, M. W. Seong, N. Kim, S. Shin, S. I. Cho, H. Park, T. S. Kim, S. S. Park, E. H.
Choi, Viral RNA load in mildly symptomatic and asymptomatic children with COVID-
19, Seoul, South Korea. *Emerg. Infect. Dis.* **26**, 2497-2499 (2020).
68. Y. Pan, D. Zhang, P. Yang, L. L. M. Poon, Q. Wang, Viral load of SARS-CoV-2 in
clinical samples. *Lancet Infect. Dis.* **20**, 411-412 (2020).
69. M. S. Han, M. W. Seong, E. Y. Heo, J. H. Park, N. Kim, S. Shin, S. I. Cho, S. S. Park, E.
H. Choi, Sequential analysis of viral load in a neonate and her mother infected with
SARS-CoV-2. *Clin. Infect. Dis.* 10.1093/cid/ciaa447 (2020).
70. H. Kawasuji, Y. Takegoshi, M. Kaneda, A. Ueno, Y. Miyajima, K. Kawago, Y. Fukui, Y.
Yoshida, M. Kimura, H. Yamada, I. Sakamaki, H. Tani, Y. Morinaga, Y. Yamamoto,
Viral load dynamics in transmissible symptomatic patients with COVID-19. medRxiv
[preprint] https://doi.org/10.1101/2020.06.02.20120014 (2020).
71. L. L. M. Poon, K. H. Chan, O. K. Wong, W. C. Yam, K. Y. Yuen, Y. Guan, Y. M. D. Lo,
J. S. M. Peiris, Early diagnosis of SARS Coronavirus infection by real time RT-PCR. *J.*
Clin. Virol. **28**, 233-238 (2003).
72. W. J. Chen, J. Y. Yang, J. H. Lin, C. S. J. Fann, V. Osyetrov, C. C. King, Y. M. A. Chen,
H. L. Chang, H. W. Kuo, F. Liao, M. S. Ho, Nasopharyngeal shedding of severe acute
respiratory syndrome-associated coronavirus is associated with genetic polymorphisms.
Clin. Infect. Dis. **42**, 1561-1569 (2006).
73. C. M. Chu, V. C. Cheng, I. F. Hung, M. M. Wong, K. H. Chan, K. S. Chan, R. Y. Kao, L.
L. Poon, C. L. Wong, Y. Guan, J. S. Peiris, K. Y. Yuen, H. U. S. S. Group, Role of
lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
Thorax **59**, 252-256 (2004).
74. L. L. Poon, K. H. Chan, O. K. Wong, T. K. Cheung, I. Ng, B. Zheng, W. H. Seto, K. Y.
Yuen, Y. Guan, J. S. Peiris, Detection of SARS coronavirus in patients with severe acute
respiratory syndrome by conventional and real-time quantitative reverse transcription-
PCR assays. *Clin. Chem.* **50**, 67-72 (2004).
75. C. M. Chu, V. C. C. Cheng, I. F. N. Hung, K. S. Chan, B. S. F. Tang, T. H. F. Tsang, K.
H. Chan, K. Y. Yuen, Viral load distribution in SARS outbreak. *Emerg. Infect. Dis.* **11**,
1882-1886 (2005).
76. I. F. Hung, V. C. Cheng, A. K. Wu, B. S. Tang, K. H. Chan, C. M. Chu, M. M. Wong, W.
T. Hui, L. L. Poon, D. M. Tse, K. S. Chan, P. C. Woo, S. K. Lau, J. S. Peiris, K. Y. Yuen,
Viral loads in clinical specimens and SARS manifestations. *Emerg. Infect. Dis.* **10**, 1550-
1557 (2004).
77. V. C. Cheng, I. F. Hung, B. S. Tang, C. M. Chu, M. M. Wong, K. H. Chan, A. K. Wu, D.
M. Tse, K. S. Chan, B. J. Zheng, J. S. Peiris, J. J. Sung, K. Y. Yuen, Viral replication in
the nasopharynx is associated with diarrhea in patients with severe acute respiratory
syndrome. *Clin. Infect. Dis.* **38**, 467-475 (2004).
78. J. S. Peiris, C. M. Chu, V. C. Cheng, K. S. Chan, I. F. Hung, L. L. Poon, K. I. Law, B. S.
Tang, T. Y. Hon, C. S. Chan, K. H. Chan, J. S. Ng, B. J. Zheng, W. L. Ng, R. W. Lai, Y.
Guan, K. Y. Yuen, H. U. S. S. Group, Clinical progression and viral load in a community
outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* **361**,
1767-1772 (2003).

79. M. Loeb, P. K. Singh, J. Fox, M. L. Russell, K. Pabbaraju, D. Zarra, S. Wong, B.
Neupane, P. Singh, R. Webby, K. Fonseca, Longitudinal study of influenza molecular
viral shedding in Hutterite communities. *J. Infect. Dis.* **206**, 1078-1084 (2012).
80. T. Suess, U. Buchholz, S. Dupke, R. Grunow, M. an der Heiden, A. Heider, B. Biere, B.
Schweiger, W. Haas, G. Krause, G. Robert Koch Institute Shedding Investigation,
Shedding and transmission of novel influenza virus A/H1N1 infection in households--
Germany, 2009. *Am. J. Epidemiol.* **171**, 1157-1164 (2010).
81. C. C. Li, L. Wang, H. L. Eng, H. L. You, L. S. Chang, K. S. Tang, Y. J. Lin, H. C. Kuo,
I. K. Lee, J. W. Liu, E. Y. Huang, K. D. Yang, Correlation of pandemic (H1N1) 2009
viral load with disease severity and prolonged viral shedding in children. *Emerg. Infect.*
Dis. **16**, 1265-1272 (2010).
82. P. X. Lu, Y. Y. Deng, G. L. Yang, W. L. Liu, Y. X. Liu, H. Huang, Y. X. Wang,
Relationship between respiratory viral load and lung lesion severity: a study in 24 cases
of pandemic H1N1 2009 influenza A pneumonia. *J. Thorac. Dis.* **4**, 377-383 (2012).
83. D. K. M. Ip, L. L. H. Lau, K. H. Chan, V. J. Fang, G. M. Leung, M. J. S. Peiris, B. J.
Cowling, The dynamic relationship between clinical symptomatology and viral shedding
in naturally acquired seasonal and pandemic influenza virus infections. *Clin. Infect. Dis.*
62, 431-437 (2016).
84. B. Rath, M. von Kleist, F. Tief, K. Karsch, E. Tuerk, S. Muehlhans, F. Louis, H. Skopnik,
B. Schweiger, S. Duwe, Virus load kinetics and resistance development during
oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and
Influenza B viruses. *Pediatr. Infect. Dis. J.* **31**, 899-905 (2012).
85. U. I. Wu, J. T. Wang, Y. C. Chen, S. C. Chang, Severity of pandemic H1N1 2009
influenza virus infection may not be directly correlated with initial viral load in upper
respiratory tract. *Influenza Other Respir Viruses* **6**, 367-373 (2012).
86. S. Meschi, M. Selleri, E. Lalle, L. Bordi, M. B. Valli, F. Ferraro, G. Ippolito, N.
Petrosillo, F. N. Lauria, M. R. Capobianchi, Duration of viral shedding in hospitalized
patients infected with pandemic H1N1. *BMC Infect. Dis.* **11**, 140 (2011).
87. J. R. Yang, J. Lo, Y. L. Ho, H. S. Wu, M. T. Liu, Pandemic H1N1 and seasonal H3N2
influenza infection in the human population show different distributions of viral loads,
which substantially affect the performance of rapid influenza tests. *Virus Res.* **155**, 163-
167 (2011).
88. C. Launes, J. J. Garcia-Garcia, I. Jordan, L. Selva, J. Rello, C. Munoz-Almagro, Viral
load at diagnosis and influenza A H1N1 (2009) disease severity in children. *Influenza*
Other Respi. Viruses **6**, e89-e92 (2012).
89. B. Killingley, J. Greatorex, S. Cauchemez, J. E. Enstone, M. Curran, R. C. Read, W. S.
Lim, A. Hayward, K. G. Nicholson, J. S. Nguyen-Van-Tam, Virus shedding and
environmental deposition of novel A (H1N1) pandemic influenza virus: interim findings.
Health Technol. Assess. **14**, 237-354 (2010).
90. N. Lee, P. K. Chan, C. K. Wong, K. T. Wong, K. W. Choi, G. M. Joynt, P. Lam, M. C.
Chan, B. C. Wong, G. C. Lui, W. W. Sin, R. Y. Wong, W. Y. Lam, A. C. Yeung, T. F.
Leung, H. Y. So, A. W. Yu, J. J. Sung, D. S. Hui, Viral clearance and inflammatory
response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus
pneumonia. *Antivir. Ther.* **16**, 237-247 (2011).
91. P. K. Chan, N. Lee, G. M. Joynt, K. W. Choi, J. L. Cheung, A. C. Yeung, P. Lam, R.
Wong, B. W. Leung, H. Y. So, W. Y. Lam, D. C. Hui, Clinical and virological course of

665		infection with haemagglutinin D222G mutant strain of 2009 pandemic influenza A
666		(H1N1) virus. *J. Clin. Virol.* **50**, 320-324 (2011).
667	92.	I. F. Hung, K. K. To, C. K. Lee, C. K. Lin, J. F. Chan, H. Tse, V. C. Cheng, H. Chen, P.
668		L. Ho, C. W. Tse, T. K. Ng, T. L. Que, K. H. Chan, K. Y. Yuen, Effect of clinical and
669		virological parameters on the level of neutralizing antibody against pandemic influenza A
670		virus H1N1 2009. *Clin. Infect. Dis.* **51**, 274-279 (2010).
671	93.	P. Q. Thai, Q. Mai le, M. R. Welkers, K. Hang Nle, T. Thanh le, V. T. Dung, N. T. Yen,
672		T. N. Duong, N. M. Hoa le, D. D. Thoang, H. T. Trang, M. D. de Jong, H. Wertheim, N.
673		T. Hien, P. Horby, A. Fox, Pandemic H1N1 virus transmission and shedding dynamics in
674		index case households of a prospective Vietnamese cohort. *J. Infect.* **68**, 581-590 (2014).
675	94.	M. Ito, S. Nukuzuma, M. Sugie, M. Yoshioka, M. Kon-no, H. Yasutake, Y. Umegaki, Y.
676		Ishikawa, T. Yano, T. Ihara, Detection of pandemic influenza A (H1N1) 2009 virus RNA
677		by real-time reverse transcription polymerase chain reaction. *Pediatr. Int.* **54**, 959-962
678		(2012).
679	95.	S. Esposito, C. Daleno, F. Baldanti, A. Scala, G. Campanini, F. Taroni, E. Fossali, C.
680		Pelucchi, N. Principi, Viral shedding in children infected by pandemic A/H1N1/2009
681		influenza virus. *Virol J.* **8**, 349 (2011).
682	96.	C. K. Lee, H. K. Lee, T. P. Loh, F. Y. Lai, P. A. Tambyah, L. Chiu, E. S. Koay, J. W.
683		Tang, Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads,
684		Singapore. *Emerg. Infect. Dis.* **17**, 287-291 (2011).
685	97.	I. W. Li, I. F. Hung, K. K. To, K. H. Chan, S. S. Wong, J. F. Chan, V. C. Cheng, O. T.
686		Tsang, S. T. Lai, Y. L. Lau, K. Y. Yuen, The natural viral load profile of patients with
687		pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. *Chest* **137**,
688		759-768 (2010).
689	98.	B. J. Cowling, K. H. Chan, V. J. Fang, L. L. H. Lau, H. C. So, R. O. P. Fung, E. S. K.
690		Ma, A. S. K. Kwong, C. W. Chan, W. W. S. Tsui, H. Y. Ngai, D. W. S. Chu, P. W. Y.
691		Lee, M. C. Chiu, G. M. Leung, J. S. M. Peiris, Comparative epidemiology of pandemic
692		and seasonal influenza A in households. *N. Engl. J. Med.* **362**, 2175-2184 (2010).
693	99.	K. K. To, K. H. Chan, I. W. Li, T. Y. Tsang, H. Tse, J. F. Chan, I. F. Hung, S. T. Lai, C.
694		W. Leung, Y. W. Kwan, Y. L. Lau, T. K. Ng, V. C. Cheng, J. S. Peiris, K. Y. Yuen, Viral
695		load in patients infected with pandemic H1N1 2009 influenza A virus. *J. Med. Virol.* **82**,
696		1-7 (2010).
697	100.	V. R. G. Alves, A. H. Perosa, L. K. de Souza Luna, J. S. Cruz, D. D. Conte, N. Bellei,
698		Influenza A(H1N1)pdm09 infection and viral load analysis in patients with different
699		clinical presentations. *Mem. Inst. Oswaldo Cruz* **115**, e200009 (2020).
700	101.	P. K. Cheng, K. K. Wong, G. C. Mak, A. H. Wong, A. Y. Ng, S. Y. Chow, R. K. Lam, C.
701		S. Lau, K. C. Ng, W. Lim, Performance of laboratory diagnostics for the detection of
702		influenza A(H1N1)v virus as correlated with the time after symptom onset and viral load.
703		*J. Clin. Virol.* **47**, 182-185 (2010).
704	102.	N. Ngaosuwankul, P. Noisumdaeng, P. Komolsiri, P. Pooruk, K. Chokephaibulkit, T.
705		Chotpitayasunondh, C. Sangsajja, C. Chuchottaworn, J. Farrar, P. Puthavathana,
706		Influenza A viral loads in respiratory samples collected from patients infected with
707		pandemic H1N1, seasonal H1N1 and H3N2 viruses. *Virol J.* **7**, 75 (2010).
708	103.	K. K. To, I. F. Hung, I. W. Li, K. L. Lee, C. K. Koo, W. W. Yan, R. Liu, K. Y. Ho, K. H.
709		Chu, C. L. Watt, W. K. Luk, K. Y. Lai, F. L. Chow, T. Mok, T. Buckley, J. F. Chan, S. S.
710		Wong, B. Zheng, H. Chen, C. C. Lau, H. Tse, V. C. Cheng, K. H. Chan, K. Y. Yuen,

Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. *Clin. Infect. Dis.* **50**, 850-859 (2010).

104. M. B. Duchamp, J. S. Casalegno, Y. Gillet, E. Frobert, E. Bernard, V. Escuret, G. Billaud, M. Valette, E. Javouhey, B. Lina, D. Floret, F. Morfin, Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful? *Clin. Microbiol. Infect.* **16**, 317-321 (2010).

105. M. Watanabe, S. Nukuzuma, M. Ito, T. Ihara, Viral load and rapid diagnostic test in patients with pandemic H1N1 2009. *Pediatr. Int.* **53**, 1097-1099 (2011).

106. P. Warnke, L. Warning, A. Podbielski, Some are more equal - a comparative study on swab uptake and release of bacterial suspensions. *PLoS One* **9**, e102215 (2014).

107. D. C. Adam, P. Wu, J. Y. Wong, E. H. Y. Lau, T. K. Tsang, S. Cauchemez, G. M. Leung, B. J. Cowling, Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. *Nat. Med.* 10.1038/s41591-020-1092-0 (2020).

108. J. Riou, C. L. Althaus, Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Euro Surveill.* **25**, (2020).

109. Y. Zhang, Y. Li, L. Wang, M. Li, X. Zhou, Evaluating transmission heterogeneity and super-spreading event of COVID-19 in a metropolis of China. *Int. J. Environ. Res. Public Health* **17**, 3705 (2020).

110. A. Tariq, Y. Lee, K. Roosa, S. Blumberg, P. Yan, S. Ma, G. Chowell, Real-time monitoring the transmission potential of COVID-19 in Singapore, March 2020. *BMC Med.* **18**, 166 (2020).

111. X. Wan, W. Wang, J. Liu, T. Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol.* **14**, 135 (2014).

112. P. Baccam, C. Beauchemin, C. A. Macken, F. G. Hayden, A. S. Perelson, Kinetics of influenza A virus infection in humans. *J. Virol.* **80**, 7590-7599 (2006).

113. H. Ikeda, S. Nakaoka, R. J. de Boer, S. Morita, N. Misawa, Y. Koyanagi, K. Aihara, K. Sato, S. Iwami, Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model. *Retrovirology* **13**, 23 (2016).

114. J. Yan, M. Grantham, J. Pantelic, P. J. Bueno de Mesquita, B. Albert, F. Liu, S. Ehrman, D. K. Milton, E. Consortium, Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 1081-1086 (2018).

115. L. L. Lau, B. J. Cowling, V. J. Fang, K. H. Chan, E. H. Lau, M. Lipsitch, C. K. Cheng, P. M. Houck, T. M. Uyeki, J. S. Peiris, G. M. Leung, Viral shedding and clinical illness in naturally acquired influenza virus infections. *J. Infect. Dis.* **201**, 1509-1516 (2010).

116. H. W. Jeong, S. M. Kim, H. S. Kim, Y. I. Kim, J. H. Kim, J. Y. Cho, S. H. Kim, H. Kang, S. G. Kim, S. J. Park, E. H. Kim, Y. K. Choi, Viable SARS-CoV-2 in various specimens from COVID-19 patients. *Clin. Microbiol. Infect.* 10.1016/j.cmi.2020.07.020 (2020).

117. G. R. Johnson, L. Morawska, Z. D. Ristovski, M. Hargreaves, K. Mengersen, C. Y. H. Chao, M. P. Wan, Y. Li, X. Xie, D. Katoshevski, S. Corbett, Modality of human expired aerosol size distributions. *J. Aerosol Sci* **42**, 839-851 (2011).

118. L. Morawska, G. R. Johnson, Z. D. Ristovski, M. Hargreaves, K. Mengersen, S. Corbett, C. Y. H. Chao, Y. Li, D. Katoshevski, Size distribution and sites of origin of droplets

expelled from the human respiratory tract during expiratory activities. *J. Aerosol Sci* **40**,
256-269 (2009).
119.   S. Asadi, A. S. Wexler, C. D. Cappa, S. Barreda, N. M. Bouvier, W. D. Ristenpart,
Aerosol emission and superemission during human speech increase with voice loudness.
Sci. Rep. **9**, 2348 (2019).

Acknowledgments: We thank T. Alba (Toronto) for discussion on statistical methods. We thank

J. Jimenez (Colorado) for discussion on the characteristics of aerosols and droplets. We thank E.

Lavezzo and A. Chrisanti (Padova) and A. Wyllie and N. Grubaugh (Yale) for responses to data

inquiries.

Funding: This work was supported by the Natural Sciences and Engineering Research Council

of Canada (NSERC) and the Toronto COVID-19 Action Fund. P.Z.C. was supported by the

NSERC Vanier Scholarship (608544). D.N.F. was supported by the Canadian Institutes of Health

Research (Canadian COVID-19 Rapid Research Fund, OV4-170360). F.X.G. was supported by

the NSERC Senior Industrial Research Chair.

Author contributions: Conceptualization, P.Z.C.; Methodology, P.Z.C., N.B., and Z.P.; Formal

Analysis, P.Z.C.; Investigation, P.Z.C. and N.B.; Resources, Z.P.; Writing – Original Draft,

P.Z.C.; Writing – Review & Editing, P.Z.C., N.B., Z.P., M.K., D.N.F., and F.X.G.;

Visualization, P.Z.C.; Supervision, M.K., D.N.F., and F.X.G; Funding Acquisition, F.X.G.

Data and materials availability: The systematic dataset and model outputs from this study are

uploaded to Zenodo (https://zenodo.org/record/4266560). The code generated during this study is

available at GitHub (https://github.com/paulzchen/sars2-heterogeneity). Search strategies for the

systematic review are shown in Tables S1 to S5. The systematic review protocol was

prospectively registered on PROSPERO (registration number, CRD42020204637).

Competing interests: The authors declare no competing interests.

Fig. 1. Development of the systematic dataset.

Fig. 2. Association of overdispersion in SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09

transmissibility with heterogeneity in rVL. Meta-regression of dispersion parameter (k) with

the standard deviation (SD) of respiratory viral loads (rVLs) from contributing studies with low

risk of bias (Pearson's r = -0.73). Pooled estimates of k were determined from the literature for

each infection. Blue, red and yellow circles denote A(H1N1)pdm09 (N = 22), COVID-19 (N =

23) and SARS (N = 7) studies, respectively. Circle sizes denote weighting in the meta-regression.

The P-value was obtained using the meta-regression slope t-test.

Subgroup, study ref.	Cases No.	Type	Specimens No.	DFSO	Type	Respiratory viral load, $\log_{10}$ copies/ml (95% CI)	P value for difference
Adult COVID-19							
45	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
46	100	H, C, A, S, Ps, As	106	-2 to 10	NPS, OPS	4.65 (4.35-4.95)	
47	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
49	14	H, A, S, As	55	0 to 10	NPS, OPS	5.30 (4.87-5.74)	
50	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
51	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
52	2,182	C, A, As	2,182	0	NPS	6.01 (5.93-6.09)	
53	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
54	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
21	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	6.21 (5.90-6.52)	
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
56	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.60)	
57	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	6.52 (5.77-7.27)	
58	39	H, A, S, As	41	0 to 10	NPS	6.71 (6.20-7.23)	
59	347	H, A, S	347	0 to 5	NPS	6.97 (6.77-7.18)	
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
61	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
62	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
63	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{20} > 100$, $P < 0.001$, $I^2 = 97.7\%$)						6.33 (5.95-6.70)	-
Pediatric COVID-19							
46	2	H, C, P, S	3	8 to 9	NPS, OPS	3.77 (1.74-5.81)	
64	7	H, P, S, Ps, As	14	-1 to 10	NPS	5.69 (5.26-6.12)	
65	54	C, P, S, Ps, As	54	-3 to 10	NPS	5.82 (5.36-6.29)	
59	58	H, P, S	58	0 to 5	NPS	6.97 (6.45-7.49)	
66	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
67	12	H, P, S, As	27	0 to 10	NPS	8.07 (7.47-8.67)	
Overall ($Q_5 = 52.1$, $P = 0.001$, $I^2 = 90.4\%$)						6.45 (5.55-7.34)	0.409
Symptomatic/presymptomatic COVID-19							
45	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
46	53	H, C, A, P, S, Ps	60	-2 to 10	NPS, OPS	4.43 (4.03-4.84)	
47	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
49	13	H, A, S	51	0 to 10	NPS, OPS	5.25 (4.79-5.71)	
68	77	H, S, Ps	119	-1 to 8	OPS, Spu	5.26 (4.63-5.90)	
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
50	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
51	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
64	6	H, P, S, Ps	13	-1 to 10	NPS	5.77 (5.10-6.53)	
65	81	C, A, P, S, Ps	81	-3 to 10	NPS	5.78 (5.41-6.15)	
21	8	H, A, S	129	2 to 10	NPS, OPS, Spu	5.88 (5.60-6.17)	
53	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
54	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
56	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.60)	
58	31	H, A, P, S	33	2 to 10	NPS	6.95 (6.37-7.53)	
59	405	H, A, P, S	405	0 to 5	NPS	6.95 (6.78-7.17)	
66	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
61	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
69	2	H, A, P, S	8	4 to 10	NPS, OPS, Spu	7.91 (6.69-9.12)	
62	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
67	9	H, P, S	20	0 to 10	NPS	8.10 (7.37-8.33)	
63	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{24} > 100$, $P < 0.001$, $I^2 = 97.0\%$)						6.38 (5.98-6.77)	-
Asymptomatic COVID-19							
46	49	H, C, A, As	49	0	NPS, OPS	4.89 (4.46-5.33)	
65	52	C, A, P, As	52	0	NPS	5.31 (4.85-5.77)	
58	9	H, A, As	9	0	NPS	5.67 (4.92-6.43)	
52	2,200	C, A, P, As	2,200	0	NPS	6.01 (5.93-6.09)	
67	3	H, P, As	7	0 to 8	NPS	8.01 (6.91-9.11)	
Overall ($Q_4 = 47.1$, $P < 0.001$, $I^2 = 91.5\%$)						5.84 (5.19-6.50)	0.107

Fig. 3. Subgroup analyses of SARS-CoV-2 rVL during the infectious period. Random-

effects meta-analyses comparing the expected respiratory viral loads (rVLs) of adult (≥18 years

old) COVID-19 cases with pediatric (<18 years old) ones (top) and symptomatic/presymptomatic

infections with asymptomatic ones (bottom) during the infectious period. Quantitative rVLs refer

to virus concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N),

community (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and

asymptomatic (As). Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate

(NPA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva

(POS) and sputum (Spu). Dashes denote case numbers that were not obtained. Box sizes denote

weighting in the overall estimates. Between-study heterogeneity was assessed using the P-value

from Cochran's Q test and the I^2 statistic. One-sided Welch's t-tests compared expected rVLs

between the COVID-19 subgroups (non-significance, $P > 0.05$).

805

806 **Fig. 4. Heterogeneity and kinetics of SARS-CoV-2 rVL. (A)** Estimated distribution of

807 respiratory viral load (rVL) for SARS-CoV-2 (N = 3,820 samples from N = 25 studies) and

808 A(H1N1)pdm09 (N = 512 samples from N = 10 studies) throughout the infectious periods. (**B**

809 and **C**) Estimated distribution of SARS-CoV-2 rVL for adult (N = 3,573 samples from N = 19

810 studies) and pediatric (N = 186 samples from N = 8 studies) (B) and asymptomatic (N = 2,221

811 samples from N = 7 studies) and symptomatic/presymptomatic (N = 1,560 samples from N = 21

812 studies) (C) COVID-19 cases. (**D**) SARS-CoV-2 rVLs fitted to a mechanistic model of viral

813 kinetics (black curve, r^2 = 0.88 for mean estimates). Filled circles and bars depict mean estimates

814 and 95% CIs. Open circles show the entirety of individual sample data over days from symptom

815 onset (DFSO) (left to right, N = 3, 15, 48, 59, 70, 73, 83, 92, 105, 133, 123, 128 and 112 samples

816 from N = 20 studies). (**E**) Estimated distributions of SARS-CoV-2 rVL across DFSO. Weibull

817 distributions were fitted on the entirety of individual sample data for the virus (A), subgroup (B

818   and C) or DFSO (E) in the systematic dataset. Arrows denote 90th case percentiles for SARS-

819   CoV-2 rVL distributions (A and E).

Fig. 5. Heterogeneity in shedding SARS-CoV-2 via droplets and aerosols. (**A** and **B**)

Estimated likelihood of respiratory particles containing viable SARS-CoV-2 when expelled by

the mean (top) or 98th case percentile (cp) (bottom) COVID-19 cases at -1 (A) or 1 (B) days from

symptom onset (DFSO). For higher no. of virions, some likelihood curves were omitted to aid

visualization. When the likelihood for 0 virions approaches 0%, particles are expected to contain

at least one viable copy. (**C** to **F**) Rate that the mean and 98th-cp COVID-19 cases at 1 DFSO

shed viable SARS-CoV-2 by talking (C), singing (D), breathing (E) or coughing (F) over particle

size. (**G**) Relative contributions of droplets and aerosols to shedding virions for each respiratory

activity (left). Relative contribution of buoyant, long-range and short-range aerosols to shedding

virions via aerosols for each respiratory activity (right). (**H**) Case heterogeneity in the total

shedding rate (over all particle sizes) of virions via singing across the infectious period. Earlier

presymptomatic days were excluded based on limited data. Data range between the 1st and 99th

cps. Lines and bands represent estimates and 95% CIs, respectively, for estimated likelihoods or

Poisson means.